How Tec kinases could make a difference in PTCL at iCML23
For quite a few years I used to ask a CTCL/PTCL expert in the poster halls whether there was anything new to report at ASH annual meetings, only to be met with a woeful hang dog look.
Despite many failed trials in this niche there are some encouraging signs beginning to emerge at last.
One story we have been following for a while has a new update worthy of discussion in terms of future directions…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers